Andrew Pollard, keynote speaker at ECCVID

We are extremely pleased to have Andrew Pollard as a keynote speaker at ECCVID! 

Register now and make sure you don’t miss his keynote lecture “News regarding COVID-19 vaccines”!

› Read more

Cast your vote in the ESCMID TAE Steering Committee Election 2020!

ECCVID Late-breaker abstract submission opening soon

Submission of late-breaker abstracts for inclusion in ECCVID will soon be opening.

Late-breaker abstracts are an opportunity for researchers to submit their new and emerging results.

Submission opens on Monday, August 24, 2020 and is open until Friday, August 28 2020 at 23:59 CEST.

› Read more

Call for ESCMID Ethics Advisory Committee members – Two weeks left to apply!

Become a member of the new Ethics Advisory Committee!

The EEAC will be an independent body meant to advise the Executive Committee (EC) and other ESCMID members on ethical issues that may arise.

If you have experience in developing and evaluating conflict of interest policies and/or an expertise in code of ethics in the scientific and medical field as well as experience and sensitisation in ethical issues management, you are welcome to send your application until 31 August 2020.

To learn more about the committee and the application procedure, please visit ESCMID website.

› Read more

Save the Date: 4th ESCMID Professional Affairs Workshop

The 4th ESCMID Professional Affairs Workshop will take place from the 23 – 26 November 2020 in an innovative online format.

The theme of this edition of the workshop is: “Being an infectious disease or a clinical microbiology specialist: challenges and opportunities”

The programme consists of a wide range of topics in infectious diseases and clinical microbiology. The current global pandemic situation has influenced the content of this workshop and will be specifically addressed.

The workshop website will be updated with the programme and registration in September.

› Read more

Submit an abstract to the 6th International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment

The understanding of the human microbiome continues to grow rapidly. However, information on the role of the microbiome on HIV infection pathogenesis, prevention and treatment is still limited. Virology Education would like to invite you to you submit an abstract to the 6th International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment, to be held virtually from October 7 to 8 2020.

The 2-day virtual event will have invited lectures by key opinion leaders, oral abstract presentations and poster presentations. The conference will be unique in its approach, as it will engage basic scientists and clinicians from the HIV field and leading scientists involved in microbiome research including bioinformatics experts. The preliminary program can be found on their website here.

The abstract submission deadline is set for August 31. They are accepting abstracts in the following topics: Pathogenesis, Microbicides/Vaccines, Comorbidities, Transmission &Prevention, Treatment & Cure and Technologies & Methodologies.  They are also offering complimentary registration to young investigators with an accepted abstract. More details can be found here. 

› Read more

EMA Annual report 2019

The European Medicines Agency’s annual report 2019 is now available on the Agency’s website. For the first time, the report is available in a digital version. You can navigate through the digital content and explore certain topics in more depth, for example through interviews and short videos. The digital version also includes an interactive timeline of the Agency’s main activities in 2019.

The first part of the report draws attention to some of the Agency’s main initiatives and challenges, including the successful relocation to Amsterdam, the development and finalisation of the ‘regulatory science strategy to 2025’, the recommendations developed by EMA and national competent authorities on big data in medicines regulation and the response to the discovery of nitrosamine impurities in medicines.

The second part is dedicated to key figures, including core statistics that summarise the main outcomes of EMA’s regulatory procedures and activities, as well as trends and changes observed in recent years.

› Read more

CMI highlight: Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea – challenges and opportunities

This review focuses on the recent scientific progress in adapting non-clinical models to accommodate research for new drugs against Neisseria gonorrhoeae, current knowledge gaps and translational challenges.

Increasing multi-drug resistance rates in N. gonorrhoeae have raised concerns and an urgent call for new antibiotics for treatment of gonorrhoea. Several decades of subdued drug development in this field and the recent failures of two new antibiotics to show non-inferiority compared to the current first-line antibiotics ceftriaxone plus azithromycin highlights the need for improved preclinical tools to predict clinical outcome of new drugs in the development process.

The published literature is here reviewed, to highlight the current knowledge of gonococcal specific PK/PD principles and provide an update on new in-vitro and in-vivo models to correlate drug exposure with clinical outcome and identify challenges and gaps in gonococcal therapeutic research.

› Read more